10:00 – 10:15 AM | Opening by Andy Topping, CSO, FUJIFILM Diosynth Biotechnologies 10:15 – 10:45 AM | Real Time Metabolomics in Biotechnology and Biopharma | Karl Burgess, Senior Lecturer...
Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...
If the current pandemic has taught us anything, it is the importance of monitoring not only our own health but the health of our loved ones. It has reiterated the...
Discounts for MassBio Member Companies: MassBio Members receive discounts on all of our courses. Check here to see if your company is a MassBio Member. If so, please contact courses@massbioed.org...
Recent history suggests a new vaccine entering human clinical trials has about a 1-in-3 chance of getting FDA approval. Stephane Bancel, chief executive of Moderna, pegs the chances of his company’s novel coronavirus vaccine at closer to 80% to 90%.